No Data
No Data
Express News | *ST Xianfeng: The company's recent business situation is normal. Currently, the main business is the veterinary vaccine business
The A-share agricultural services sector fluctuated and rose. *ST Xianfeng closed the market, Lukang Biochemical rose more than 4%, and Keqian Biotech, Dayu Water Saving, and Huilong Yongshun Biotech all became popular.
The A-share agricultural services sector fluctuated and rose. *ST Xianfeng closed the market, Lukang Biochemical rose more than 4%, and Keqian Biotech, Dayu Water Saving, and Huilong Yongshun Biotech all became popular.
The A-share animal vaccine sector boosted Placo by more than 5%
Glonghui, May 21 | Placo rose more than 5%, *ST Xianfeng rose more than 4%, and Jinhe Biotech, Tiankang Biotech, Sinopharm Hyundai, and Luoniushan followed suit.
*ST Xianfeng (002141.SZ): Initial repurchase of 1.051,000 shares involving 1,038,200 yuan
Gelonghui, May 17丨*ST Xianfeng (002141.SZ) announced that on May 17, 2024, for the first time, the company repurchased 1,0501.07 million shares of the company's shares through a special stock repurchase account, accounting for 0.09% of the company's total share capital (based on the company's total share capital as of May 17, 2024). The maximum transaction price was 0.99 yuan/share, and the minimum transaction price was 0.98 yuan/share, with a transaction amount of 1,038,200 yuan (excluding transaction fees).
*ST Xianfeng (002141.SZ) received a warning letter from the Guangdong Securities Regulatory Bureau
Zhitong Finance App News, *ST Xianfeng (002141.SZ) issued an announcement. The company received the “Decision on Issuing Warning Letter Measures against Xianfeng Holdings Co., Ltd., Han Peach, Ding Chen, Xie Wenbin, Zhang Yangyu, etc.” ([2024] No. 39) issued by the Guangdong Securities Regulatory Bureau on May 16, 2024. After investigation, on April 26, 2024, Xianfeng Holdings disclosed the “Notice on Correction of Early Accounting Errors” because the company Chengdu Shiji Biopharmaceutical Co., Ltd. (hereinafter referred to as Shiji Biotech) improperly confirmed its main business revenue and inflated revenue, which led to the company's first quarter report of 2023
Express News | *ST Xianfeng: Plans to repurchase shares for 50 million yuan to 100 million yuan
No Data